[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351974-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351974-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plasma-acylcarnitine-dysregulation-associated-with-cpt1-mediated-metabolism-contributes-to-oral-carcinogenesis","Plasma acylcarnitine dysregulation associated with CPT1-mediated metabolism contributes to oral carcinogenesis","","Plasma acylcarnitine dysregulation is examined for its connection to CPT1-mediated lipid metabolic reprogramming in oral cancer (OC). Semi-targeted and targeted plasma metabolomic profiling was performed in a discovery cohort (182 OC, 364 healthy controls) with independent external validation (52 OC, 52 HC). Machine learning and targeted validation identified markedly downregulated medium-chain acylcarnitines, while pathway enrichment indicated altered β-oxidation and glycerophospholipid metabolism. CPT1 expression was elevated in OC tissues and cells, and CPT1 inhibition reduced OC cell growth and changed acylcarnitine profiles.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plasma-acylcarnitine-dysregulation-associated-with-cpt1-mediated-metabolism-contributes-to-oral-carcinogenesis/351974/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plasma-acylcarnitine-dysregulation-associated-with-cpt1-mediated-metabolism-contributes-to-oral-carcinogenesis/351974.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What metabolite changes are linked to oral cancer in this study?","Question",{"text":63,"@type":64},"Medium-chain acylcarnitines, specifically decanoyl-, octanoyl-, and hexanoylcarnitine, are markedly downregulated in oral cancer plasma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CPT1 relate to the lipid metabolic findings?",{"text":68,"@type":64},"CPT1 expression is elevated in oral cancer tissues and cells, and pharmacological CPT1 inhibition suppresses oral cancer cell growth while altering acylcarnitine profiles.",{"name":70,"@type":61,"acceptedAnswer":71},"How were the plasma metabolomic results validated?",{"text":72,"@type":64},"Initial discovery profiling was followed by independent external validation, using machine learning to select discriminatory metabolites and targeted validation to confirm consistent changes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351974,1791218502,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPlasma acylcarnitine dysregulation associated with CPT1-mediated metabolism contributes to oral carcinogenesis  \nYeon-Hee Kim1,4, Sung Weon Choi2,4, Jong Ho Lee2, Joo Yong Park2, Heesun Cheong3 & Mi Kyung Kim1􀀍  \nGrowing evidence suggests that lipid metabolic reprogramming occurs in oral cancer (OC). We characterized circulating metabolic alterations associated with lipid metabolic reprogramming in  \nOC. Semi-targeted and targeted plasma metabolomic profiling was performed in a discovery cohort (182 OC, 364 healthy controls [HC]) followed by independent external validation (52 OC, 52 HC) . Machine learning approaches were used to identify plasma metabolites with strong discriminatory performance between patients with OC and healthy controls. Targeted validation confirmed consistent metabolic changes. Namely, three medium-chain acylcarnitines—decanoyl-, octanoyl-, and hexanoylcarnitine—were markedly downregulated inOC plasma, demonstrating consistent and reproducible discrimination during external validation (AUC = 0.941, 95% CI: 0.877–0.988) . Pathway enrichment analysis further suggested altered β-oxidation and glycerophospholipid metabolism in OC. We also observed elevated carnitine palmitoyltransferase 1 (CPT1) expression in OC tissues and cells. Moreover, pharmacological inhibition ofCPT1 suppressed OC cell growth and altered acylcarnitine profiles. These findings support an association between circulating acylcarnitine alterations and CPT1-related lipid metabolic reprogramming in OC. Furthermore, they provide biological context supporting the association between circulating metabolic alterations and CPT1-related lipid metabolic reprogramming in OC.  \nKeywords Acylcarnitines, Carnitine palmitoyltransferase 1, Lipid metabolism, Metabolomics, Fatty acid β-oxidation, Oral cancer  \nOral cancer (OC) is one of the most common malignancies, with 377,713 new cases of lip and oral cavity cancer and 177,757 deaths being reported in 2020 by the GLOBOCAN project1. The 5-year survival rate for OC ranges from 15% to 50% for patients with stages III and IV disease, but exceeds 80% if early diagnosed (stages I or II)2,3. Indeed, early detection of OC markedly improves survival and quality of life, as is associated with a reduced need of invasive/aggressive treatments and better response to therapy. Currently, diagnosis relies on multiple biopsies and histopathological assessments, which can be burdensome for patients4. Therefore, identifying non-invasive biomarkers of OC is crucial for improving diagnosis and prognosis.  \nProgression of oral squamous cell carcinoma, which accounts for over 90% of all OC cases5, reportedly occurs under conditions of limited oxygen and nutrient supply6. Additionally, lipid reprogramming was reported to support tumor growth by increasing fatty acid uptake and synthesis, while also altering lipid storage7. During carcinogenesis, creatine phosphokinase levels decrease and fatty acids are diverted towards the rapid proliferation of cancer cells via fatty acid oxidation (FAO)6,8. Carnitine palmitoyltransferase (CPT), a key enzyme regulating FAO, was also reported to be upregulated in cancer cells exposed to adipocytes or fatty acids9. Of note, dysregulation of acylcarnitine metabolism, which is mediated by CPT1 at the outer mitochondrial membrane10, was associated with the progression of various cancers, including gastric, colorectal, and lung adenocarcinoma11. Despite its importance, only three studies have investigated lipid-related carcinogenesis in  \n1Cancer Epidemiology Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, 323 Ilsandong-gu, Goyang-si 10408, Gyeonggi-do, Republic of Korea. 2Oral Oncology Clinic, Research Institute & Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea. 3Cancer Metastasis Branch, Division of Cancer Biology, National Cancer Center, Goyang-si, Gyeongg","cbCaivCRbgq159gx","https://ap.wps.com/l/cbCaivCRbgq159gx","pdf",3886475,13,"English","# Background\n## Oral cancer burden and need for biomarkers\n## Lipid reprogramming and CPT1 in carcinogenesis\n## Rationale for plasma metabolomics\n# Methods\n## Study participants and sample collection","[{\"question\":\"What metabolite changes are linked to oral cancer in this study?\",\"answer\":\"Medium-chain acylcarnitines, specifically decanoyl-, octanoyl-, and hexanoylcarnitine, are markedly downregulated in oral cancer plasma.\"},{\"question\":\"How does CPT1 relate to the lipid metabolic findings?\",\"answer\":\"CPT1 expression is elevated in oral cancer tissues and cells, and pharmacological CPT1 inhibition suppresses oral cancer cell growth while altering acylcarnitine profiles.\"},{\"question\":\"How were the plasma metabolomic results validated?\",\"answer\":\"Initial discovery profiling was followed by independent external validation, using machine learning to select discriminatory metabolites and targeted validation to confirm consistent changes.\"}]","Plasma acylcarnitine dysregulation associated with CPT1-mediated metabolism contributes to oral carcinogenesis | PDF",1790096641,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88b2bdcd80ee349772564a6cd4d6c541.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37f6ae5e5465ccd22c8970411f2b1c10.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc6af1a6889c38bf4dd2cb6dcd3aa228.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca07e09a087c609801858b64cb76ca45.webp",980,1287]